AstraZeneca to pay Pfizer $107.5M in damages in Tagrisso patent tussle

Pfizer, through its Wyeth unit, is entitled to receive $107.5 million in damages from AstraZeneca after a Delaware federal jury on Friday found that the British-Swedish pharma’s cancer drug Tagrisso (osimertinib) violated patent protections.